Literature DB >> 24316625

Biocon's first-in-class anti-CD6 mAb reaches the market.

Killugudi Jayaraman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24316625     DOI： 10.1038/nbt1213-1062b

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Ustekinumab poised to enter the psoriasis market.

Authors:  Charlie Schmidt
Journal:  Nat Biotechnol       Date:  2008-12       Impact factor: 54.908

2.  A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

Authors:  Pedro C Rodriguez; Roberto Torres-Moya; Gil Reyes; Claudino Molinero; Dinorah Prada; Ana M Lopez; Isabel M Hernandez; Maria V Hernandez; Jose P Martinez; Xochel Hernandez; Angel Casaco; Mayra Ramos; Yisel Avila; Yinet Barrese; Enrique Montero; Patricia Hernandez
Journal:  Results Immunol       Date:  2012-11-21
  2 in total
  9 in total

1.  CD6 as a potential target for treating multiple sclerosis.

Authors:  Yan Li; Nora G Singer; Joy Whitbred; Michael A Bowen; David A Fox; Feng Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-16       Impact factor: 11.205

2.  CD318 is a ligand for CD6.

Authors:  Gospel Enyindah-Asonye; Yan Li; Jeffrey H Ruth; Danislav S Spassov; Katie E Hebron; Andries Zijlstra; Mark M Moasser; Benlian Wang; Nora G Singer; Huadong Cui; Ray A Ohara; Stephanie M Rasmussen; David A Fox; Feng Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-31       Impact factor: 11.205

3.  Targeting CD6 for the treatment of experimental autoimmune uveitis.

Authors:  Lingjun Zhang; Yan Li; Wen Qiu; Brent A Bell; Nina Dvorina; William M Baldwin; Nora Singer; Timothy Kern; Rachel R Caspi; David A Fox; Feng Lin
Journal:  J Autoimmun       Date:  2018-02-19       Impact factor: 7.094

4.  Structures of CD6 and Its Ligand CD166 Give Insight into Their Interaction.

Authors:  Paul E Chappell; Lee I Garner; Jun Yan; Clive Metcalfe; Deborah Hatherley; Steven Johnson; Carol V Robinson; Susan M Lea; Marion H Brown
Journal:  Structure       Date:  2015-07-02       Impact factor: 5.006

Review 5.  Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.

Authors:  Roshni Menon; Brinda G David
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-17

6.  Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.

Authors:  Marta Consuegra-Fernández; Mario Martínez-Florensa; Fernando Aranda; José de Salort; Noelia Armiger-Borràs; Teresa Lozano; Noelia Casares; Juan José Lasarte; Pablo Engel; Francisco Lozano
Journal:  Front Immunol       Date:  2017-05-30       Impact factor: 7.561

7.  Modulation of CD4 T cell function via CD6-targeting.

Authors:  Raquel Filipa Freitas; Afonso Basto; Silvia C P Almeida; Rita F Santos; Carine M Gonçalves; Jesus Corria-Osorio; Tânia Carvalho; Alexandre M Carmo; Vanessa G Oliveira; Kalet Leon; Luis Graca
Journal:  EBioMedicine       Date:  2019-08-31       Impact factor: 8.143

Review 8.  Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents.

Authors:  María Velasco-de Andrés; Sergi Casadó-Llombart; Cristina Català; Alejandra Leyton-Pereira; Francisco Lozano; Fernando Aranda
Journal:  Cells       Date:  2020-12-03       Impact factor: 6.600

9.  CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action.

Authors:  Lee I Garner; Andrew Hartland; Johannes Breuning; Marion H Brown
Journal:  Immunology       Date:  2018-06-13       Impact factor: 7.397
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.